Panacea Biotec Secures INR 20.79 Crore Vaccine Supply Contract
Filing Summary
Panacea Biotec Ltd has received a Letter of Award from the Central Medical Services Society, Ministry of Health and Family Welfare, Government of India. The contract involves the supply of Diphtheria and Tetanus Vaccine (Absorbed) for Adults and Adolescents IP, valued at INR 20.79 Crore. The supply will occur in several tranches from September/October 2026 to November/December 2028. This agreement is a domestic contract and does not involve any related party transactions. The company has no promoter interest in the awarding entity.
Panacea Biotec Ltd has been awarded a contract by the Central Medical Services Society (CMSS), Ministry of Health and Family Welfare, Government of India. The contract, formalized through a Letter of Award dated April 10, 2026, mandates the supply of Diphtheria and Tetanus Vaccine (Absorbed) for Adults and Adolescents IP. The total value of the contract is INR 20.79 Crore.
The supply of the vaccine will be executed in multiple tranches, commencing from September/October 2026 and concluding by November/December 2028. This contract is classified as a domestic order, with no international involvement. The terms of the agreement specify that the supply is to be completed within the stipulated timeline.
According to the filing, there is no interest from the promoter or promoter group of Panacea Biotec in the entity awarding the contract. Additionally, the transaction does not qualify as a related party transaction, ensuring that it is conducted at arm’s length.
The Central Medical Services Society operates under the Ministry of Health and Family Welfare, focusing on the procurement and distribution of medical supplies across India. Its primary objective is to ensure the availability of essential medicines and vaccines to various health programs and institutions.
Panacea Biotec Ltd is a biotechnology company engaged in the research, development, manufacturing, and marketing of pharmaceutical formulations, vaccines, and biosimilars. The company prioritizes innovation in healthcare solutions and aims to address critical health challenges through its product offerings.